|
FeyeCon Carbon Dioxide Technologies today
entered into a technology acquisition agreement
with the Malaysian Biotechnology Corporation (BiotechCorp).
The agreement, worth several million Euros,
outlines the transfer of FeyeCon developed
industrial biotechnology to BiotechCorp. The
technology focuses on natural product production
and development. The world market for natural
products is currently valued at US$ 80 billion,
with Malaysia moving to become a key player in
the market.
“The natural product industry is set to become
another important source of revenue generation
for the country [Malaysia],” asserts Dato
Iskandar Mizal Mahmood, CEO of BiotechCorp.
FeyeCon, a medium sized Dutch technology
development company, has been involved with
natural product research for the past 10 years.
The deal with BiotechCorp represents a major
step in rolling out carbon dioxide technology in
Asia.
FeyeCon uses carbon dioxide to develop novel
products and processes which have applications
in a variety of industrial fields. Last year
FeyeCon established FeyeCon Asia Sdn Bhd in
Kuala Lumpur to address Asia’s increasing
interest in FeyeCon’s various food and
pharmaceutical production and product
technologies. “After our launching customer on
May 6th this year, this marks a quantum leap in
the Asia technology role out”, says Toine
Paijens Director of FeyeCon Asia Sdn Bhd.
Dr. Geert Woerlee, CEO of FeyeCon explains:
“Whilst many small and medium sized companies
are struggling under currently unfavorable
economic conditions, Asia has demonstrated
itself to be an interesting outlet for European
technology. We look forward to future
collaboration between the two continents.”
Source:
FeyeCon Carbon
Dioxide Technologies
|
